- BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma studyBeOne Medicines said its BTK inhibitor Brukinsa cut the risk of disease progression or death by 43% compared to chemoimmunotherapy when used as a first option for mantle cell lymphoma patients. T…Endpoints · 26d ago↗ source
- House China panel probes Bristol Myers, Pfizer on use of trial sitesA congressional committee has opened an inquiry into Bristol Myers Squibb and Pfizer's use of clinical trial sites in China, including facilities that the committee's chairman said are affiliated w…Endpoints · 26d ago↗ source
- NEJM retracts pivotal data for Amgen's TavneosPivotal data for Amgen’s Tavneos have been retracted from the New England Journal of Medicine, creating another obstacle for the beleaguered autoimmune drug. Two academic authors requested the re…